The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...
Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...
Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 ...
The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...
INSIDER on MSN11d
The FDA has banned Red No. 3, a synthetic dye used in candy, cereals, and ADHD medicationDrug companies, like Takeda, the maker of Vyvanse, have until 2028. Red No. 3 is present in about a quarter of baking ...
Global biopharmaceutical giant Takeda opens its first Asian Innovation Capability Centre in Bengaluru to speed up drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback